Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Clostridium Stories

2011-04-02 13:00:00

SAN DIEGO, April 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI. Investigator Erik R. Dubberke, M.D., M.S.P.H., of the Washington...

2011-03-30 08:30:00

DISPATCH® Towels with Bleach have the fastest EPA registered kill time for Clostridium difficile OAKLAND, Calif., March 30, 2011 /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that the U.S. Environmental Protection Agency (EPA) approved the registration of DISPATCH® Hospital Cleaner Disinfectant Towels with Bleach to kill Clostridium difficile (C. difficile) spores in five minutes(1), the fastest C. difficile contact time available(2)....

2011-03-30 07:11:00

GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for Xeomin® (incobotulinumtoxinA). Merz expects that this unique billing code, which will become effective on April 1, 2011, will help simplify the billing and reimbursement process for prescribers of XEOMIN. The U.S. Food and Drug...

2011-03-21 23:34:45

Stress can change the balance of bacteria that naturally live in the gut, according to research published this month in the journal Brain, Behavior, and Immunity. "These bacteria affect immune function, and may help explain why stress dysregulates the immune response," said lead researcher Michael Bailey. Exposure to stress led to changes in composition, diversity and number of gut microorganisms, according to scientists from The Ohio State University. The bacterial communities in the...

2011-03-08 07:11:00

GREENSBORO, N.C., March 8, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced the launch of two programs to provide financial assistance to patients for their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum toxin type A free from accessory proteins that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with cervical dystonia, to decrease the severity of abnormal head position and neck pain in both botulinum...

2011-03-07 15:32:16

Scientists on the Norwich Research Park have sequenced the genome of a novel strain of Clostridium botulinum, one of the most dangerous pathogens known to man. The strain produces an unusual botulinum neurotoxin, known as type A5 neurotoxin, which was isolated by the Health Protection Agency (HPA), following a case of wound botulism. Professor Mike Peck and his research group at the Institute of Food Research (IFR) study Clostridium botulinum. Their expertise is crucial for preventing food...

2011-03-02 14:31:11

Transplanted enzyme pathway makes E. coli churn out n-butanol University of California, Berkeley, chemists have engineered bacteria to churn out a gasoline-like biofuel at about 10 times the rate of competing microbes, a breakthrough that could soon provide an affordable and "green" transportation fuel. The development is reported online this week in advance of publication in the journal Nature Chemical Biology by Michelle C. Y. Chang, assistant professor of chemistry at UC Berkeley, graduate...

2011-03-02 00:00:28

A new, safe alternative antimicrobial formula to displace traditional highly-toxic sporicidal disinfectants could help reduce the growing number of hospital-acquired Clostridum difficile-related infections. Farmington Hills, MI (Vocus/PRWEB) March 01, 2011 UrthTech, a Farmington Hills, Michigan based company, announced today that it found its patented Urthâ“ž¢ chemical technology is an effective antimicrobial agent against Clostridium difficile (C. diff) spores....

2011-02-14 07:00:00

SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that former ViroPharma executive, Glenn Tillotson, Ph.D., has joined Optimer as Senior Vice President of Medical Affairs; Sherwood Gorbach, M.D., has been promoted to the position of Chief Scientific Officer and Senior Vice President of Research and Development; and Marc Lesnick, Ph.D., has been promoted to the newly created position of Vice President of Regulatory Affairs. (Logo:...

2011-02-02 12:15:00

SAN DIEGO, Feb. 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only...


Latest Clostridium Reference Libraries

0_d6572564d3305dc462f4641398789e11
2011-04-15 13:32:47

Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...

More Articles (1 articles) »